Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.

Luker AJ, Graham LJ, Smith TM Jr, Camarena C, Zellner MP, Gilmer JS, Damle SR, Conrad DH, Bear HD, Martin RK.

BMC Immunol. 2020 Feb 27;21(1):8. doi: 10.1186/s12865-020-0337-5.

2.

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.

Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N.

Lancet. 2019 Dec 14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. Epub 2019 Dec 5.

PMID:
31813636
3.

If we build it they will come: targeting the immune response to breast cancer.

Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA.

NPJ Breast Cancer. 2019 Oct 29;5:37. doi: 10.1038/s41523-019-0133-7. eCollection 2019. Review.

4.

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters.

Bear HD, McGuire KP.

Ann Surg Oncol. 2019 Aug;26(8):2316-2318. doi: 10.1245/s10434-019-07401-z. Epub 2019 Apr 24. No abstract available.

PMID:
31020504
5.

Erratum: Re: Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):917-923.

Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP.

J Surg Oncol. 2018 Sep;118(4):722. doi: 10.1002/jso.24798. Epub 2017 Jul 28. No abstract available.

PMID:
30295942
6.

Generosity and Duration of Medicaid Expansion Waivers and Access to Care.

Tarazi WW, Bradley CJ, Harless DW, Bear HD, Sabik LM.

Am J Prev Med. 2018 Nov;55(5):624-632. doi: 10.1016/j.amepre.2018.06.020. Epub 2018 Sep 14.

PMID:
30224224
7.

Gr1-/low CD11b-/low MHCII+ myeloid cells boost T cell anti-tumor efficacy.

Payne KK, Aqbi HF, Butler SE, Graham L, Keim RC, Wan W, Idowu MO, Bear HD, Wang XY, Manjili MH.

J Leukoc Biol. 2018 Dec;104(6):1215-1228. doi: 10.1002/JLB.5A0717-276RR. Epub 2018 Jul 9.

8.

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy.

Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH.

Oncotarget. 2018 Apr 24;9(31):22113-22122. doi: 10.18632/oncotarget.25197. eCollection 2018 Apr 24.

9.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

10.

Papillary lesions of the breast: To excise or observe?

Khan S, Diaz A, Archer KJ, Lehman RR, Mullins T, Cardenosa G, Bear HD.

Breast J. 2018 May;24(3):350-355. doi: 10.1111/tbj.12907. Epub 2017 Aug 27.

PMID:
28845569
11.

Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.

Tarazi WW, Bradley CJ, Bear HD, Harless DW, Sabik LM.

Cancer. 2017 Sep 1;123(17):3312-3319. doi: 10.1002/cncr.30771. Epub 2017 Jun 26.

12.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.

Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP.

J Surg Oncol. 2017 Jun;115(8):917-923. doi: 10.1002/jso.24610. Epub 2017 Apr 13. Erratum in: J Surg Oncol. 2018 Sep;118(4):722.

13.

Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.

Zoon CK, Wan W, Graham L, Bear HD.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E270. doi: 10.3390/ijms18020270.

14.

Angiopoietin pathway gene expression associated with poor breast cancer survival.

Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K.

Breast Cancer Res Treat. 2017 Feb;162(1):191-198. doi: 10.1007/s10549-017-4102-2. Epub 2017 Jan 6.

15.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Ann Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.

16.

Modified breast cancer model for preclinical immunotherapy studies.

Katsuta E, DeMasi SC, Terracina KP, Spiegel S, Phan GQ, Bear HD, Takabe K.

J Surg Res. 2016 Aug;204(2):467-474. doi: 10.1016/j.jss.2016.06.003. Epub 2016 Jun 8.

17.

DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.

Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, Bear HD.

Cancer Immunol Immunother. 2016 Sep;65(9):1061-73. doi: 10.1007/s00262-016-1868-8. Epub 2016 Jul 14.

18.

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.

Payne KK, Keim RC, Graham L, Idowu MO, Wan W, Wang XY, Toor AA, Bear HD, Manjili MH.

J Leukoc Biol. 2016 Sep;100(3):625-35. doi: 10.1189/jlb.5A1215-580R. Epub 2016 Feb 29.

19.

Medicaid expansion and access to care among cancer survivors: a baseline overview.

Tarazi WW, Bradley CJ, Harless DW, Bear HD, Sabik LM.

J Cancer Surviv. 2016 Jun;10(3):583-92. doi: 10.1007/s11764-015-0504-5. Epub 2015 Dec 11.

20.

A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA; ACRIN 668 Investigative Team.

J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.

21.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

22.

Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study.

Aboalela N, Lyon D, Elswick RK Jr, Kelly DL, Brumelle J, Bear HD, Jackson-Cook C.

PLoS One. 2015 Jul 15;10(7):e0133380. doi: 10.1371/journal.pone.0133380. eCollection 2015.

23.

Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.

Zoon CK, Wan W, Graham L, Bear HD.

Int J Mol Sci. 2015 Apr 20;16(4):8744-60. doi: 10.3390/ijms16048744.

24.

Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.

Youniss FM, Sundaresan G, Graham LJ, Wang L, Berry CR, Dewkar GK, Jose P, Bear HD, Zweit J.

PLoS One. 2014 Oct 21;9(10):e109162. doi: 10.1371/journal.pone.0109162. eCollection 2014.

25.

Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.

Payne KK, Bear HD, Manjili MH.

Future Oncol. 2014 Aug;10(10):1779-94. doi: 10.2217/fon.14.97. Review. Erratum in: Future Oncol. 2014 Oct;10(13):2098.

PMID:
25303057
26.

Expansion of melanoma-specific lymphocytes in alternate gamma chain cytokines: gene expression variances between T cells and T-cell subsets exposed to IL-2 versus IL-7/15.

Zoon CK, Seitelman E, Keller S, Graham L, Blevins TL, Dumur CI, Bear HD.

Cancer Gene Ther. 2014 Oct;21(10):441-7. doi: 10.1038/cgt.2014.48. Epub 2014 Sep 19.

27.

Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells.

Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM, Conrad DH.

J Leukoc Biol. 2014 Jul;96(1):151-9. doi: 10.1189/jlb.5A1213-644R. Epub 2014 Mar 7.

28.

Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.

Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO, Faber TW, Pullen NA, Kolawole EM, Brooks KB, Norton SK, Sturgill J, Graham L, Bear HD, Urban JF Jr, Lantz CS, Conrad DH, Ryan JJ.

J Leukoc Biol. 2014 Apr;95(4):643-50. doi: 10.1189/jlb.0913510. Epub 2013 Dec 12.

29.

Intraoperative injection of radiocolloid for sentinel node biopsy in breast cancer.

Vu HN, O'Connor PF, Shoemaker RR, Wan W, Fratkin MJ, Bear HD.

J Nucl Med Technol. 2013 Dec;41(4):263-7. doi: 10.2967/jnmt.113.129460. Epub 2013 Nov 14.

30.

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

Payne KK, Zoon CK, Wan W, Marlar K, Keim RC, Kenari MN, Kazim AL, Bear HD, Manjili MH.

Breast Cancer Res Treat. 2013 Nov;142(1):45-57. doi: 10.1007/s10549-013-2733-5. Epub 2013 Oct 25.

31.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.

PMID:
24095300
32.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH.

J Transl Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145.

33.

The role of margin status and reexcision in local recurrence following breast conservation surgery.

Adams BJ, Zoon CK, Stevenson C, Chitnavis P, Wolfe L, Bear HD.

Ann Surg Oncol. 2013 Jul;20(7):2250-5. doi: 10.1245/s10434-012-2831-3. Epub 2013 May 18.

PMID:
23686015
34.

Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.

Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K.

Surgery. 2013 Jun;153(6):771-8. doi: 10.1016/j.surg.2013.02.002. Epub 2013 Mar 13.

35.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N.

J Clin Oncol. 2012 Nov 10;30(32):3960-6. doi: 10.1200/JCO.2011.40.8369. Epub 2012 Oct 1.

36.

Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.

Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH.

J Immunol. 2012 Jul 15;189(2):511-5. doi: 10.4049/jimmunol.1200647. Epub 2012 Jun 15.

37.

Bevacizumab and breast cancer: what does the future hold?

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K.

Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22. Review.

38.

Insurance and inpatient care: differences in length of stay and costs between surgically treated cancer patients.

Bradley CJ, Dahman B, Bear HD.

Cancer. 2012 Oct 15;118(20):5084-91. doi: 10.1002/cncr.27508. Epub 2012 Mar 13.

39.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

N Engl J Med. 2012 Jan 26;366(4):310-20. doi: 10.1056/NEJMoa1111097.

40.

Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.

Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Bear HD, Logan J, McCumisky J, Moorman-Sykes K, Adler S, Choyke PL.

J Nucl Med. 2011 Sep;52(9):1339-45. doi: 10.2967/jnumed.111.091587. Epub 2011 Aug 17.

41.

A gene transcription signature of obesity in breast cancer.

Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC.

Breast Cancer Res Treat. 2012 Apr;132(3):993-1000. doi: 10.1007/s10549-011-1595-y. Epub 2011 Jul 13.

PMID:
21750966
42.

Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells.

Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD, Ginder GD.

Mol Cancer Res. 2011 Aug;9(8):1152-62. doi: 10.1158/1541-7786.MCR-11-0252. Epub 2011 Jun 21.

43.

Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH.

J Immunol. 2011 Jul 15;187(2):708-17. doi: 10.4049/jimmunol.1100502. Epub 2011 Jun 13.

44.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients.

Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH.

Breast Cancer Res Treat. 2012 Feb;131(3):871-80. doi: 10.1007/s10549-011-1470-x. Epub 2011 Apr 11.

45.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.

Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD, Manjili MH.

J Transl Med. 2011 Mar 31;9:35. doi: 10.1186/1479-5876-9-35.

46.

Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.

Kmieciak M, Toor A, Graham L, Bear HD, Manjili MH.

J Vis Exp. 2011 Jan 14;(47). pii: 2381. doi: 10.3791/2381.

48.

Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy.

Bear HD.

Surg Oncol Clin N Am. 2010 Jul;19(3):607-26. doi: 10.1016/j.soc.2010.04.001. Review.

PMID:
20620930
49.

Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.

Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL Jr, Gewirtz DA.

Breast Cancer Res Treat. 2010 Nov;124(2):349-60. doi: 10.1007/s10549-010-0765-7. Epub 2010 Feb 13.

PMID:
20155316
50.

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH.

Breast Cancer Res Treat. 2010 Aug;123(1):39-49. doi: 10.1007/s10549-009-0622-8. Epub 2009 Nov 8.

Supplemental Content

Support Center